Exploring the clinical relevance of LMTK3 in Glioblastoma
Research type
Research Study
Full title
Exploring the clinical relevance of Lemur Tyrosine Kinase 3 in Glioblastoma: A Feasibility Study
IRAS ID
207340
Contact name
George Giamas
Contact email
Sponsor organisation
University of Sussex
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
Glioblastoma (GBM) is the commonest malignant primary brain tumour amongst the adult population with incidence rates of around 4.6/100,000 in the UK population. It is a devastating disease with average life expectancy in range of 12-15 months. Standard treatment was established in 2005 and involves surgery followed by a combination of chemotherapy and radiotherapy. Since 2005 there has been little progress in terms of new effective treatment regimes. It is vitally important to understand the biology of these tumours in order to try and develop more targetted treatments.
LMTK3 can work as an 'on/off' switch for many processes within a cancer cell. It has been shown to be present in brain tumour cells and in higher concentrations in more aggressive tumours. It has also been shown to have a relationship with overall survival within breast cancer patients. The exact nature of its role within GBM tumours is not fully established. As yet, work done LMTK3 in GBM has been performed on cell lines or commercially available tissue microarrays. We seek to explore whether it is feasible to examine for LMTK3 expression levels in an unselected sample of archived GBM specimens. We also aim to look further at the mechanisms by which LMTK3 works and whether there is a similar relationship with survival within GBM patients.
REC name
London - Surrey Borders Research Ethics Committee
REC reference
16/LO/1378
Date of REC Opinion
21 Jul 2016
REC opinion
Favourable Opinion